Table 2.
Vaccine effectiveness and relative vaccine effectiveness in pooled study
| Day | First dose ChAdOx1a | Second dose ChAdOx1a | First dose BNT162b2b | Second dose BNT162b2b |
|---|---|---|---|---|
| 14 | 47 (50 to 52) | 38 (22 to 50) | 64 (60 to 67) | 71 (63 to 78) |
| 28 | 50 (38 to 60) | 36 (15 to 52) | 69 (61 to 75) | 70 (58 to 79) |
| 42 | 36 (15 to 51) | 33 (8 to 51) | 62 (49 to 71) | 60 (42 to 72) |
| 56 | 50 (29 to 65) | 26 (–4 to 47) | 55 (37 to 68) | 54 (30 to 69) |
| 70 | –25 (–80 to 14) | 10 (–32 to 39) | 42 (9 to 64) | 53 (26 to 70) |
| 84 | –185 (–73 to –369) | –19 (–94 to 27) | –121 (–14 to –326) | 58 (30 to 75) |
| 98 | –89 (–15 to –212) | –59 (–247 to 27) | –85 (1 to 46) | 46 (13 to 67) |
a
Oxford–AstraZeneca.
b
Pfizer–BioNTech.